340B ACCESS Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The 340B ACCESS Act (H.R. 8574) is a legislative proposal introduced in the 118th Congress aimed at addressing issues related to the 340B Drug Pricing Program, which allows certain healthcare providers to purchase outpatient drugs at reduced prices. The bill was referred to the House Subcommittee on Health but did not advance further and is currently classified as failed or expired. Specific provisions, objectives, and detailed legislative text are not available in the provided data.
H.R. 8574 sought to amend or impact the 340B Drug Pricing Program but did not progress beyond referral to a subcommittee and ultimately expired without enactment.
- The bill is titled the 340B ACCESS Act and relates to the health policy area.
- It was introduced in the House of Representatives during the 118th Congress.
- The latest recorded action was referral to the Subcommittee on Health on December 17, 2024.
- No official summary or full text is available to detail the bill's specific provisions.
- The bill status is marked as failed or expired, indicating it did not pass into law.
["Potential beneficiaries would likely include healthcare providers participating in the 340B Drug Pricing Program and the patients they serve, depending on the bill's provisions.", 'Pharmaceutical purchasers and entities involved in outpatient drug pricing could also be affected.']
['Lack of available full text and summary limits understanding of implementation requirements and oversight mechanisms.', 'Without detailed provisions, it is unclear how the bill would affect costs or authority related to the 340B program.', "The bill's failure to advance may reflect challenges in legislative support or competing priorities."]
The 340B Drug Pricing Program has been subject to ongoing legislative and regulatory attention due to its impact on drug pricing and healthcare provider reimbursements. This bill was introduced during the 118th Congress but did not advance beyond a subcommittee referral stage before expiring. The absence of further action suggests limited legislative momentum for this specific proposal during the session.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, changes to the 340B program could influence drug pricing dynamics and healthcare provider financial operations.', 'Potential shifts in outpatient drug access or pricing could indirectly affect patient care costs and provider participation.', 'Legislative attention to the 340B program may signal ongoing policy debates impacting future healthcare funding and regulation.']
Transparency is limited due to the absence of the bill's full text and official summary, which are essential for thorough public and legislative review. The bill's failure to progress beyond subcommittee referral and its expired status highlight the importance of tracking legislative developments and ensuring access to complete documentation for effective government oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.